Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Pluri Inc. Regulatory Filings 2012

Sep 5, 2012

6990_rns_2012-09-05_d2a16a1f-1bee-4b97-b0f4-54602f6d3a7e.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

8-K 1 zk1211974.htm 8-K zk1211974.htm Licensed to: ZK Global Document Created using EDGARizer 2020 5.4.3.1 Copyright 1995 - 2009 Thomson Reuters. All rights reserved.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 5, 2012

PLURISTEM THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Nevada 001-31392 98-0351734
(State or other jurisdiction of incorporation) (Commission file number) (I.R.S. Employer Identification Number)
MATAM Advanced Technology Park Building No. 20 Haifa, Israel 31905 31905
(Address of principal executive offices)

Registrant’s telephone number, including area code: 011 972 74 710 7171

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On September 5, 2012, the registrant announced that the registrant’s Placental eXpanded (PLX) cells were successfully administered to a third patient in Hadassah Medical Center; thus, a series of three life saving compassionate use treatments were completed.

SIGNATURES EFPlaceholder

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Yaky Yanay
Yaky Yanay
Chief Financial Officer